Clinical Trials Logo

Polycythemia Vera clinical trials

View clinical trials related to Polycythemia Vera.

Filter by:

NCT ID: NCT00522574 Terminated - Myelofibrosis Clinical Trials

A Safety Study of XL019 in Adults With Myelofibrosis

Start date: August 2007
Phase: Phase 1
Study type: Interventional

The purpose of this study is to evaluate the safety and tolerability of XL019 in adults with myelofibrosis. XL019 is a selective inhibitor of the cytoplasmic tyrosine kinase JAK2. JAK2 is activated by cytokine and growth factor receptors and phosphorylates members of the STAT family of inducible transcription factors. Activation of the JAK/STAT pathway promotes cell growth and survival, and is a common feature of human tumors. JAK2 is activated by mutation in the majority of patients with myelofibrosis, polycythemia vera and essential thrombocytosis and appears to drive the inappropriate growth of blood cells in these conditions.